Autopsy report · NCT03515785

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Revisiting the availability of patients with Ph+ ALL that would meet the in-/exclusion criteria of the study led to the decision not to move forward.”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Sponsor: Incyte Biosciences International Sàrl
Sponsor type: Industry
Conditions: BCR-ABL Positive Acute Lymphoblastic Leukemia
Participants: 0
Sites: 10
Countries: Czechia, France, Germany

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.